AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36287929
Drug: High indoxyl
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High indoxyl sulfate (IS) levels (cutoff 0.365 mg/dL)
Trial: 36287929
Drug: High myostatin
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High myostatin levels (cutoff 4.5 ng/mL)
Trial: 36288547
Drug: Teliso-V (2.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teliso-V (2.7 mg/kg once every 21 days) plus erlotinib (150 mg once daily)
Trial: 36288714
Drug: v-ATPase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: v-ATPase inhibitors (e.g., etidronate)
Trial: 36288714
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of etidronate
Trial: 36288758
Drug: Stereotactic Ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic Ablative Radiotherapy (SAbR) with a median prescribed dose of 45 Gy (range, 35-55) in 5 daily fractions to tumor and 40 Gy (35-45) to nodes.
Trial: 36289094
Drug: Lenvatinib 20
RxNorm normalized name: LENVATINIB 20MG DAILY DOSE PACK,10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib 20 mg/day plus Pembrolizumab 200 mg every 3 weeks
Trial: 36291912
Drug: MEMMAT-like metronomic
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEMMAT-like metronomic antiangiogenic approach including daily oral thalidomide, fenofibrate, celecoxib, alternating 21-day cycles of low-dose oral etoposide and cyclophosphamide, IV bevacizumab, and intraventricular therapy with alternating etoposide and liposomal cytarabine.
Trial: 36294516
Drug: Invasive endovascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive endovascular treatment for CVS
Trial: 36295001
Drug: COVID-19 convalescent
RxNorm normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 convalescent plasma (CCP) transfusion (single unit with anti-RBD IgG concentration > 5 AU/mL)
Trial: 36301137
Drug: Pembrolizumab (PD-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (PD-1 inhibitor)
Trial: 36301604
Drug: Mindfulness training
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindfulness training via a smartphone app (10 weekly sessions, daily practice)
Trial: 36301928
Drug: Dissolved tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dissolved tablet of EVG/COBI/FTC/TAF
Trial: 36301928
Drug: Whole tablet
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole tablet of EVG/COBI/FTC/TAF
Trial: 36302175
Drug: Guadecitabine (subcutaneously,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guadecitabine (subcutaneously, 45 mg/m2/day for 5 consecutive days, planned 28-day cycle)
Trial: 36302562
Drug: Ivuxolimab (0.1-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivuxolimab (0.1-3 mg/kg every 2 weeks) + utomilumab (20 or 100 mg every 4 weeks)
Trial: 36302562
Drug: Ivuxolimab (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivuxolimab (30 mg every 2 weeks) + utomilumab (20 mg every 4 weeks)
Trial: 36302579
Drug: Weekly physical
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly physical education (PE) and recess minutes in 2020
Trial: 36302584
Drug: Baseline eGFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline eGFR <45 mL/min/1.73 m²
Trial: 36302584
Drug: Baseline eGFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline eGFR 45-60 mL/min/1.73 m²
Trial: 36302584
Drug: Baseline eGFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline eGFR >60 mL/min/1.73 m²
Trial: 36303108
Drug: Regional citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional citrate anticoagulation with continuous infusion of 8% trisodium citrate into the arterial line and supplementation of 1 M calcium chloride into the venous line
Trial: 36303332
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioural therapy program
Trial: 36304240
Drug: Preventive measures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive measures (e.g., social distancing, mask usage)
Trial: 36304457
Drug: Pembrolizumab 2
RxNorm normalized name: pembrolizumab 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 2 mg/kg every 3 weeks for ≤35 cycles
Trial: 36305957
Drug: Ipatasertib 400
RxNorm normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipatasertib 400 mg once-daily orally
Trial: 36306154
Drug: Waitlist control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist control group maintaining daily activities.
Trial: 36306158
Drug: Training Intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training Intervention and Program of Support (TIPS) consisting of a 1-month training intervention with self-paced learning modules and a webinar, followed by an 11-month support program including monthly site meetings and access to a virtual community of practice.
Trial: 36307410
Drug: Ad-sig-hMUC1/ecdCD40L adenoviral-vector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad-sig-hMUC1/ecdCD40L adenoviral-vector vaccine
Trial: 36307775
Drug: SCT200 (anti-EGFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCT200 (anti-EGFR monoclonal antibody) administered intravenously every 3 weeks at doses ranging from 0.5-15.0 mg/kg.
Trial: 36307826
Drug: Eribulin, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin, administered for a median of 4.5 cycles (1-23 cycles), with a median overall survival of 12 months.
Trial: 36307845
Drug: Intraoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative radiation therapy (IORT) 15 Gy/1 fraction after SBRT 40 Gy/5 fractions
Trial: 36308640
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 100 mg CBD:100 mg THC
Trial: 36309488
Drug: High-intensity inspiratory
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity inspiratory muscle training (IMT) at home, 80% of max, daily in Phase 1 and 2, once weekly in Phase 3, self-selected frequency in Phase 4, with one weekly supervised session except Phase 4
Trial: 36309837
Drug: Epacadostat (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epacadostat (300 mg) plus durvalumab
Trial: 36309981
Drug: Venetoclax (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (100, 200, or 400 mg daily for 14 days every 28-day cycle) + Azacitidine (75 mg/m² on Days 1-7 every cycle)
Trial: 36310395
Drug: Qualitative interviews
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualitative interviews with unvaccinated ED patients regarding COVID-19 vaccination concerns and potential approaches to increase vaccine acceptance.
Trial: 36310566
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor (PPI) with feeding modifications
Trial: 36310566
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor (PPI) alone
Trial: 36313145
Drug: Orelabrutinib 150
RxNorm normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orelabrutinib 150 mg orally daily until disease progression or unacceptable toxicity
Trial: 36314160
Drug: POC whole-blood
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POC whole-blood hs-cTnI assay (Atellica VTLi) with a threshold of <4 ng/L
Trial: 36314198
Drug: Cannabis inhalation
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis inhalation
Trial: 36314999
Drug: First Booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First Booster of SARS-COV-2 mRNA Vaccine
Trial: 36315224
Drug: Daily SMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily SMS text message reminders to follow their chosen anchoring plan (messages group; treatment group 1)
Trial: 36315224
Drug: Daily SMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily SMS text messages and incentives conditional on taking their ART medication around the time of their chosen anchor (incentives group; treatment group 2)
Trial: 36316061
Drug: INCAGN01949 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCAGN01949 monotherapy (7-1400 mg) in 14-day cycles
Trial: 36316628
Drug: Oral L-citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-citrulline (150 mg/kg)
Trial: 36316733
Drug: FPG value
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPG value (≥ 92 mg/dl) following Italian Diabetes Societies recommendations for COVID 19 pandemic period
Trial: 36317254
Drug: Regenerative peripheral
RxNorm normalized name: Regener-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regenerative peripheral nerve interfaces and intramuscular electrodes
Trial: 36318387
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg (qw or q2w)
Trial: 36318494
Drug: Bifactor solution
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifactor solution of DSM-XC
Trial: 36318879
Drug: Intravenous dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dose of 40 IU of vasopressin with epinephrine
Trial: 36319569
Drug: Treatment dissatisfaction
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment dissatisfaction (PAC-QOL)
Trial: 36319717
Drug: Intratumoral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratumoral administration of CV8102
Trial: 36319717
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of i.t. CV8102 with systemic anti-PD-1 treatment
Trial: 36319944
Drug: STOPP/START-based in-hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STOPP/START-based in-hospital medication review
Trial: 36320022
Drug: Stimulant medication
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant medication for ADHD
Trial: 36322113
Drug: MindShift CBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MindShift CBT app plus treatment as usual (TAU) over 6 days
Trial: 36322714
Drug: Bone marrow-derived,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow-derived, allogeneic MSCs (75 million MSCs administered via direct injection, with repeat injection at 3 months if needed)
Trial: 36322714
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no MSC therapy)
Trial: 36322782
Drug: 4-week mobile
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week mobile health (mHealth) prescription to monitor for AF recurrences
Trial: 36322825
Drug: Dasatinib/prednisone induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib/prednisone induction followed by blinatumomab/dasatinib postremission therapy for 3 cycles and dasatinib/prednisone maintenance.
Trial: 36322825
Drug: Blinatumomab reinduction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinatumomab reinduction therapy for patients not achieving response by day 56.
Trial: 36322825
Drug: Central nervous
RxNorm normalized name: CENTRAL NERVOUS SYSTEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Central nervous system prophylaxis with intrathecal methotrexate for a total of 8 doses.
Trial: 36323235
Drug: BMS-963272 (MGAT2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-963272 (MGAT2 inhibitor)
Trial: 36323235
Drug: Selective DGAT1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective DGAT1 inhibitor
Trial: 36323435
Drug: Nivolumab (anti-PD-1)
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) combination therapy
Trial: 36323435
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4
Trial: 36323444
Drug: Dapagliflozin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin with standard therapy
Trial: 36323464
Drug: Maternal antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal antibiotic treatment during pregnancy
Trial: 36323612
Drug: Afatinib (first-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (first-line treatment)
Trial: 36324098
Drug: Androgen receptor
RxNorm normalized name: Androgen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen receptor (AR) CAG repeats
Trial: 36324191
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment for trigger finger
Trial: 36325355
Drug: FCR treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCR treatment (fludarabine-cyclophosphamide-rituximab)
Trial: 36325389
Drug: KIO-100 (PP-001),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KIO-100 (PP-001), a small molecule DHODH-inhibitor
Trial: 36326731
Drug: Immunotherapy (IO)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (IO)
Trial: 36326731
Drug: Non-immunotherapy systemic
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-immunotherapy systemic anticancer therapies (non-IO)
Trial: 36327378
Drug: Family-Based Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-Based Treatment delivered by videoconferencing (FBT-V)
Trial: 36328033
Drug: Trastuzumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab plus FOLFOX (intravenous trastuzumab-pkrb at 6 mg/kg on day 1, FOLFOX regimen with intravenous oxaliplatin [85 mg/m2])
Trial: 36328377
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses, followed by nivolumab 480 mg every 4 weeks for up to 2 years or until progression, toxicity, or protocol-specified discontinuation.
Trial: 36328399
Drug: Three-dose primary
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dose primary SARS-CoV-2 vaccination in patients with IMID
Trial: 36328399
Drug: Two-dose primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose primary SARS-CoV-2 vaccination in healthy controls
Trial: 36328399
Drug: Third dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third dose of vaccination
Trial: 36328399
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of antibody decline rates
Trial: 36328851
Drug: Extended-release naltrexone
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naltrexone and case management services
Trial: 36328851
Drug: Baseline daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline daily alcohol consumption
Trial: 36330013
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (including drug-coated balloon, directional atherectomy, supera, and drug-eluting stent)
Trial: 36330140
Drug: Whole-grain wheat
RxNorm normalized name: rice (whole grain) allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-grain wheat (WGW) intervention (98 g/d)
Trial: 36330484
Drug: Buparlisib, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib, an oral pan-PI3K inhibitor, administered for a median of 4.5 months (range 2-33).
Trial: 36330484
Drug: Buparlisib, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib, an oral pan-PI3K inhibitor.
Trial: 36330490
Drug: Apatinib 500
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 500 mg
Trial: 36330490
Drug: Apatinib 750
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 750 mg
Trial: 36330490
Drug: Apatinib 850
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 850 mg
Trial: 36330525
Drug: Arginase-1 peptide
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arginase-1 peptide vaccine (three 20-mer peptides from the ARG1 immunological 'hot spot' region with Montanide ISA-51 adjuvant, administered subcutaneously every third week, maximum 16 vaccines)
Trial: 36330525
Drug: Arginase-1 peptide
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arginase-1 peptide vaccine
Trial: 36331674
Drug: Orally-administered bendamustine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally-administered bendamustine hydrochloride, dosages ranging from 175 to 840 mg/m2, administered once daily for 7, 14, and 21 days every 3 weeks as one cycle.
Trial: 36331676
Drug: CA102N (0.72
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA102N (0.72 mg/kg Nim equivalent)
Trial: 36331676
Drug: CA102N in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA102N in combination with trifluridine-tipiracil
Trial: 36331681
Drug: CBA in
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBA in antiarrhythmic drug (AAD)-refractory patients
Trial: 36332763
Drug: Dupilumab 200
RxNorm normalized name: dupilumab 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 200 mg and 300 mg every 2 weeks
Trial: 36332953
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral tenofovir/emtricitabine (TDF/FTC) with adherence self-management interventions (point-of-care urine drug-level assay, HIV self-testing, weekly text messaging)
Trial: 36332964
Drug: IL-6 antagonist
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6 antagonist therapy
Trial: 36333464
Drug: Camidanlumab tesirine
RxNorm normalized name: Camidanlumab tesirine
DrugBank: Camidanlumab tesirine (DB16411)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camidanlumab tesirine (Cami); specific dosage and duration not mentioned.
Trial: 36333616
Drug: Atopic Dermatitis
RxNorm normalized name: SALICYLIC ACID 20 mg in 1 g TOPICAL CREAM [DermaD ATOPIC DERMATITIS Therapeutic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atopic Dermatitis Impact Scale (ADerm-IS) Daily Activities
Trial: 36333618
Drug: Spesolimab 600-mg
RxNorm normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spesolimab 600-mg loading dose followed by 300-mg maintenance dose every 4 weeks
Trial: 36333618
Drug: Spesolimab 600-mg
RxNorm normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spesolimab 600-mg loading dose followed by 300-mg maintenance dose every 12 weeks
Trial: 36333618
Drug: Spesolimab 300-mg
RxNorm normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spesolimab 300-mg loading dose followed by 150-mg maintenance dose every 12 weeks
Trial: 36333676
Drug: Glucose control
RxNorm normalized name: Glucose Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose control treatment group
Trial: 36334048
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral glutamine supplementation
Trial: 36334289
Drug: MRI-guided focused
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI-guided focused ultrasound (FUS) treatment targeting the hippocampus, frontal lobe, and parietal lobe, with 3 separate treatment sessions performed 2 weeks apart.
Trial: 36334289
Drug: MRI-guided focused
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI-guided focused ultrasound (FUS) treatment
Trial: 36335079
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy from the quitline
Trial: 36335079
Drug: Any pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any pharmacotherapy